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Abstract
Background: Circulating tumor DNA (ctDNA) is a biomarker for the selection
of target agents in various malignancies. In this study, we examined the effect of
ctDNA presence on the response to EGFR-tyrosine kinase inhibitor (TKI) and
on the prognosis in lung adenocarcinoma.
Methods: ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitu-
tion and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital
PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR
in the corresponding tumor tissues.
Results: The study recruited lung cancer patients at various stages, and the sen-
sitivity, specificity, and area under the curve (AUC) of mEGFR ctDNA detection
by ddPCR were 40.0%, 88.5%, and 0.68, respectively. It showed higher sensitivity
(75.0% vs. 10.0%) and AUC (0.83 vs. 0.49) in the advanced stages of lung adeno-
carcinoma compared with the early stages and the number of metastases and the
fractional abundance of mEGFR ctDNA showed a strong correlation (σ = 0.516;
P < 0.001, Spearman correlation test). There was a significantly shorter
progression-free survival and duration of disease control by EGFR-TKIs in the
ctDNA-positive group than the negative group (14.0 vs. 41.0 months, P = 0.02
and 12.0 vs. 23.0 months, P = 0.02, log-rank test, respectively). There was a trend
for overall survival time to be shorter in patients with mEGFR ctDNA than for
patients without mEGFR ctDNA (35.6 vs. 67.1 months, P = 0.06, log-rank test).
Conclusions: These data showed that mEGFR ctDNA detection using ddPCR is
useful in the advanced stages and its presence predicted distant metastasis and
poor clinical outcome in lung adenocarcinoma.
Introduction
In 2018, approximately two million people were diagnosed
with lung cancer globally, accounting for 11.6% of the total
cancer incidence and the death toll from this devastating dis-
ease was 1.76 million, accounting for 18.4% of cancer-related
deaths, remaining the most common cause of cancer-related
deaths to date.1 A total of 85% of lung cancers are non-small
cell lung cancer (NSCLC). More than 50% of NSCLC patients
present with distant metastasis at the time of diagnosis, which
cannot be cured by surgical resection alone.2
Drug-sensitizing mutations in the tyrosine kinase domain
of the epidermal growth factor receptor (mEGFRs) occur
frequently in lung adenocarcinomas of women, never
smokers, and Asians. In Korea, mEGFRs are found in 40%
of lung adenocarcinomas.3 Large-scale phase III clinical trials
have been performed in patients with mEGFR-positive lung
adenocarcinoma and showed a higher response rate and
prolonged progression-free survival (PFS) in the group
treated with EGFR tyrosine kinase inhibitors (TKIs) com-
pared to those treated with cytotoxic chemotherapy. When
EGFR mutations were present in the tissues, the therapeutic
response to EGFR-TKIs was more than 70%.4–8 As a result,
EGFR-TKIs are widely used as the standard treatment
option for mEGFR-positive lung adenocarcinoma.
When a small amount of specimen is collected, it may
be inadequate to use for genetic testing, including testing
for EGFR mutations. In this case, liquid biopsies can be
used for adjunctive diagnostic testing. The detection of
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circulating tumor DNA (ctDNA) is used for the selection
of the most suitable diagnostic option. Currently, Cobas
amplification refractory mutation system (ARMS, Cobas
EGFR Mutation Test v2), next-generation sequencing
(NGS)-based methods, peptide nucleic acid (PNA)-
mediated PCR, and droplet digital PCR (ddPCR) methods
can be used to detect ctDNA in liquid biopsies from
NSCLC patients. Of these methods, Cobas II and PNA-
mediated PCR are approved in the Republic of Korea.9
Recently, ddPCR, which is one of the most sensitive
methods, has been used to detect EGFR mutant ctDNA in
NSCLC patients.10–13 However, there are limited studies on the
interpretation of ddPCR results, the cutoff values, and the clin-
ical implication of these values. Therefore, the aim of this
study was to determine the cutoff values and the clinical impli-
cations of ddPCR parameters measured in plasma samples.
Methods
Patients
We analyzed the results of patients as follows: (i) Had a
pathologically confirmed lung adenocarcinoma; (ii) EGFR
mutation status was confirmed in the tumor tissue;
(iii) Computed tomography had been used to evaluate the
primary lesion size; (iv) No previous therapy had been
experienced before blood sampling; and (v) The patient
agreed to provide blood samples. Both EGFR L858R substi-
tution and exon 19 deletion (E19d) mutation tests were
performed by ddPCR on collected blood samples.
All patients provided their written informed consent.
This study was performed in accordance with the amended
Declaration of Helsinki, following approval of the study by
an independent hospital institutional review board
(approval No. 3-2016-0225 and 3-2017-0321).
Plasma collection and DNA extraction
In eligible patients, plasma was collected using a Streck
tube (Dow Biomedica, Seoul, Korea). The collected blood
was centrifuged at 1000 × g for 10 minutes within the
same working day and the supernatant was separated and
stored at −80C until DNA extraction. ctDNA was
extracted from the plasma using a QIAamp circulating
nucleic acid kit (Qiagen, Hilden, Germany), according to
the manufacturer’s instructions.
ddPCR
ddPCR was performed according to the manufacturer’s
manual (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Mutation sites were detected using probes for EGFR
L858R (BR186dHsaCP2000021; Bio-Rad) and Exon19del
(BR12002392, Bio-Rad). ddPCR was performed by first
forming droplets with a QX100 Droplet Generator (Bio-
Rad). PCR amplification was then performed within each
droplet using a thermal cycler (Bio-Rad). Following PCR,
droplets were streamed in single file on a QX200 Droplet
Reader (Bio-Rad), which counts the fluorescent-positive
and fluorescent-negative droplets to calculate the target
DNA concentration. Data were processed using QuantaSoft
software (Bio-Rad). The threshold values of the ddPCR
results were determined using QuantaSoft software and
then manually validated. ddPCR results passed quality con-
trol when the number of droplets was more than 9000 and
the wild-type gene sequence was present in more than
100 copies/mL. Only data that passed initial quality control
were used for analysis.
ddPCR test results yielded three parameters: concentra-
tion, mutant/wild-type ratio, and fractional abundance.
Area under the curve (AUC) values were calculated to
determine which of the three parameters were most consis-
tent with that from tumor tissue. For E19d results, the
AUC values were 0.67 for the concentration, the mutant/
wild type ratio, and fractional abundance. The AUC values
for the L858R results were 0.66 for the concentration, the
mutant/wild-type ratio, and fractional abundance. There
were no significant differences in these values and the
commonly used fractional abundance parameter was used
for further analysis. Results were defined as positive when
the fractional abundance was greater than 0.1%.
Statistical analysis
Categorical and continuous parameters were evaluated
using a Chi-square test or an independent sample t-test,
respectively. The Spearman correlation test was used to test
relationships between two variables. Survival curves were
generated using the Kaplan-Meier method. P-values less
than 0.05 were considered significant. Statistical analyses
were performed using SPSS version 23.0 for Windows
(SPSS, Chicago, IL, USA) or R Statistical Package (Institute
for Statistics and Mathematics, Vienna, Austria, ver 3.5.3,
www.R-project.org).
Results
Clinical characteristics of study population
To confirm the robustness of ddPCR testing parameters and
determine the appropriate cutoff value, 81 patients who had
been diagnosed with lung adenocarcinoma and underwent
tissue EGFR mutation testing were recruited. The baseline
characteristics of the patients are presented in Table 1. The
mean age of the patients was 64.0  1.1 years; there were
43 (53.1%) males, and 52 (64.2%) patients had no smoking
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history. The stage distribution in patients was as follows:
stage I in 25 (30.9%), stage II in six (7.4%), stage III in
14 (17.3%), and stage IV in 36 (44.4%) patients. A total of
31 (38.3%) patients showed the wild-type EGFR genotype,
20 (24.7%) the L858R, and 24 (29.6%) the E19d mutant.
The receiver operating characteristic (ROC) curve analy-
sis was then performed to evaluate the representativeness
of plasma ctDNA on tumor tissue mutation status and
AUC values were calculated. In this cohort comprised of
heterogeneous stages, the AUC of plasma ddPCR analysis
was 0.67 (95% CI, 0.56–0.77) for E19d and 0.66 (95% CI,
0.53–0.79) for L858R. Plasma ddPCR analysis showed high
specificity for the detection of E19d (91.2%) and L858R
(96.7%). The sensitivity of the plasma ddPCR method was
modest for E19d (41.7%) and L858R (40.0%) (Figure S1a,
d). The diagnostic applicability of the plasma ddPCR
method for mEGFR detection was analyzed without dis-
criminating between E19d and L858R (Fig 1a). As a result,
the AUC was 0.68 (95% CI, 0.58–0.77), the sensitivity was
40.0%, and the specificity was 88.5% for all stages.
ctDNA showed higher correspondence in
advanced lung adenocarcinoma
We further analyzed the data according to the stage, with early
stage defined as stages I–IIIA and advanced stage as stages
IIIB–IV. In patients with early stage disease, the AUC of the
plasma ddPCR analysis was 0.46 (95% CI, 0.41–0.51) for E19d
(Figure S1b) and 0.51 (95% CI, 0.38–0.64) for L858R
(Figure S1e). The sensitivity was 0.0% for E19d and 11.1% for
L858R and the specificity was 92.3% for E19d and 100.0% for
L858R. When the detection rates of L858R and E19d mutants
were analyzed together in early-stage patients, the AUC was
0.49 (95% CI, 0.37–0.61), the sensitivity was 10.0%, and the
specificity was 100.0% (Fig 1b). In the advanced stage patients,
the AUC of the plasma ddPCR analysis was 0.84 (95% CI,
0.71–0.98) for E19d (Figure S1c) and 0.79 (95% CI, 0.62–0.96)
for L858R (Figure S1f). The sensitivity was 76.9% for E19d
and 63.6% for L858R and the specificity was 90.3% for E19d
and 97.0% for L858R. When the detection rates of L858R and
E19d mutants were analyzed together in the advanced-stage
patients, the AUC was 0.83 (95% CI, 0.71–0.94), the sensitivity
was 75.0%, and the specificity was 85.0% (Fig 1c). Taken
together, the agreement between the plasma ddPCR results
and that of the tissue biopsy genotype increased in advanced
stage, suggesting the mEGFR detection by ddPCR is only
applicable in the advanced stage.
Relationship of number of distant
metastatic sites to presence of mEGFR
ctDNA
To investigate the clinical factors associated with the presence
of mEGFR ctDNA in the blood, a correlation analysis was
performed between the clinical parameters and the fractional
abundance from ddPCR analysis. First, the relationship
between TNM stage and plasma ctDNA fractional abundance
was analyzed (Table 2). As the TNM stage increased, the pro-
portion of ctDNA EGFR mutation tended to increase. There
was no significant difference in the fractional abundance value
of mEGFR ctDNA with the progression of T stage and N
stage (Figure S2). Regarding the M stage, there was a signifi-
cant difference in the fractional abundance value in those
with and without distant metastasis (0.45  0.24% in M0 and
8.71  3.14% in M1, P < 0.001). In addition, the correlation
between the number of metastatic sites and plasma ctDNA
fractional abundance was analyzed, and there was a strong
correlation (σ = 0.516, P < 0.001, Spearman correlation test,
Fig 2d). The most common metastatic sites in stage IV
patients were bone (44.4%, 16/36) and the brain (33.3%,
12/36). There was also a significant difference in the fractional
Table 1 Baseline characteristics of lung adenocarcinoma
patients (n = 81)
Variables Total (No.) %
Mean age, years 64.0  1.1
Sex
Male 43 53.1
Female 38 46.9
Smoking history
Never smoker 52 64.2
Ex-smoker 22 27.2
Current smoker 7 8.6
T stage
Primary tumor size, cm 3.67  2.57
T1 24 29.6
T2 23 28.4
T3 9 11.1
T4 25 30.9
N stage
N0 39 48.1
N1 1 1.2
N2 19 23.5
N3 22 27.2
M stage
Metastatic sites 0.73  1.03
M0 47 58.0
M1 34 42.0
Stage
I 25 30.9
II 6 7.4
III 14 17.3
IV 36 44.4
EGFR mutation
Wild 31 38.3
L858R 20 24.7
E19del 24 29.6
Others 6 7.4
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abundance values in patients with or without bone metastasis
(Fig 2b) and brain metastasis (Fig 2c). Therefore, the detec-
tion of plasma ctDNA is useful as a surrogate marker for
predicting distant metastasis.
Presence of mEGFR ctDNA predicts a poor
clinical outcome in lung adenocarcinoma
The prognostic significance of plasma ctDNA detection
was analyzed in 81 lung adenocarcinoma patients. Of the
81 patients, 52 (64.2%) were mEGFR ctDNA negative and
29 (35.8%) were positive. The PFS and overall survival
(OS) of the patients were analyzed divided to mEGFR
ctDNA positive group and mEGFR ctDNA negative group
(Fig 3). The median PFS of lung adenocarcinoma patients
was 22.0 months (95% CI, 15.8~28.2 months). According
to Kaplan-Meier survival curves, the ctDNA positive group
had significantly shorter PFS than the ctDNA negative
group (14.0 vs. 41.0 months, P = 0.02, log-rank test, Fig 3a).
The mean OS was 58.3  3.7 months (95% CI, 51.0–
65.5 months). Although statistical significance was not
reached, the OS of the ctDNA positive group was shorter
Figure 1 ROC analysis of plasma ddPCR assay of NSCLC tissue samples. (a) Overall stage, (b) Early stage (I–IIIA), and (c) Advanced stage (IIIB–IV).
Table 2 The relationship between the parameters related to the TNM staging and plasma ctDNA fraction abundance
N (%) 81(100) Fraction abundance (%) P-value ctDNA EGFR mutation (%)
T stage 0.001* 0.01***
T1 24 (29.6) 0.55  0.52 3/24 (12.5)
T2 23 (28.4) 2.63  1.80 6/23 (26.1)
T3 9 (11.1) 0.11  0.11 1/9 (11.1)
T4 25 (30.9) 3.76  1.58 13/25(52.0)
N stage 0.004* 0.013***
N0 39 (48.1) 0.52  0.47 5/39 (12.8)
N1 1 (1.2) NA 0/1 (0)
N2 19 (23.5) 2.82  1.84 8/19 (42.1)
N3 22 (27.2) 4.32  1.95 10/22 (45.5)
M stage <0.001** <0.001***
M0 47 (58.0) 0.69  0.47 6/47 (12.8)
M1 34 (42.0) 4.01  1.57 17/34 (50.0)
Stage <0.001** 0.001***
I 25 (30.9) 0.15  0.01 2/25 (8)
II 6 (7.4) 0.02  0.02 0/6 (0)
III 14 (17.3) 0.96  0.89 3/14 (21.4)
IV 36 (44.4) 4.29  1.54 18/36 (50.0)
Brain metastasis <0.001**
No 69 (85.2) 1.41  0.60
Yes 12 (14.8) 5.98  3.44
Bone metastasis
No 65 (80.2) 0.45  0.24 <0.001**
Yes 16 (19.8) 8.71  3.14
*Kruskal-Wallis test. **Mann-Whitney U test. ***Chi-square test.
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than that of the ctDNA negative group (35.6  3.20
vs. 67.1  1.88 months, P = 0.06, log-rank test, Fig 3b). A
subgroup analysis was performed in 27 patients who had
been diagnosed with mEGFR-positive lung adenocarci-
noma and received EGFR-TKI treatment. Among the
26 patients, five (19.2%) were plasma ctDNA negative and
21 (80.8%) were plasma ctDNA positive. PFS after the ini-
tiation of EGFR-TKI treatment was analyzed in these two
groups. The median PFS time of patients taking EGFR-
TKIs was 13.0 months (95% CI: 8.86–17.1 months). The
duration of disease control by EGFR-TKIs was 11 months
shorter in the plasma ctDNA positive group than the
ctDNA negative group (12.0 vs. 23.0 months, P = 0.02, log-
rank test, Fig 3c). In conclusion, the presence of mEGFR
ctDNA was associated with poor survival in lung adenocar-
cinoma patients and poor treatment response to EGFR-
TKI treatment.
Discussion
In this study, we demonstrated the high sensitivity and
specificity of plasma ctDNA detection in NSCLC patients.
The plasma ddPCR assay used in this study was similar to,
or improved, compared with other ctDNA genotyping
Figure 2 Correlation between ddPCR fractional abundance for EGFR mutations and clinical parameters: (a) M stage, (b) Brain metastasis, (c) Bone
metastasis, and (d) the number of metastatic sites.
Figure 3 Survival analysis according to the presence of EGFR mutations in ctDNA. (a) PFS, (b) OS in lung adenocarcinoma (n = 81) and (c) PFS in lung
adenocarcinoma patients treated with EGFR-TKIs (n = 27). ( ) ctDNA negative, ( ) ctDNA positive, ( ) Censored ctDNA negative, and ( )
Censored ctDNA positive.
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assays.14–19 Previous studies have investigated the detection
of plasma ctDNA only in patients with advanced NSCLC.
In contrast, this study compared plasma ctDNA detection
rates in early and advanced stages of NSCLC. These results
showed that the plasma ddPCR assay was only useful in
the advanced stage because it had relatively low diagnostic
yields in the early stage. This study demonstrated the use-
fulness of a ddPCR-based plasma genotyping assay was
dependent on the cancer stage.
Previous studies have reported correlations between
plasma ctDNA and factors associated with TNM staging.
Lee et al. reported that plasma ctDNA is not correlated
with primary tumor size, but is significantly correlated with
the number of metastatic sites.16 Couraud et al. demon-
strated that plasma ctDNA concentration was significantly
associated with both cancer stage and the number of meta-
static sites.17 Jia et al. showed that higher ctDNA quantities
are correlated with bone metastasis.20 Similarly, this study
showed that the detection of plasma ctDNA is significantly
correlated with distant metastasis, especially in bone and
brain metastasis.
In this study, five patients were EGFR mutation positive
in plasma but negative in tissue samples. All false-positive
plasma samples resulted with L858R mutation and frac-
tional abundance was 0.03, 0.12, 0.13, 0.13 and 0.16,
respectively. Although the possibility of experimental arti-
facts could not be totally excluded, these inconsistencies in
the EGFR mutation status between tissue and blood sam-
ples may be due to the heterogeneity of the tumor.21
Oxnard et al. revealed the presence of resistance point
mutation T790M mutation in 78% of the 18 discordant
cases (plasma positive/tissue negative).22 This study also
showed that patients who were positive for T790M in
plasma had the same treatment outcomes with third-
generation TKIs (eg. osimertinib) as patients where the
mutation was evident in tissue samples. Therefore, even if
there is wild-type in tissue samples, close monitoring of
prognosis is necessary if the patient’s blood sample is
mEGFR positive. In our data, five cases of false-positive
cases were reported: two in stage I, one in stage II, and two
in stage IV. One patient with stage IV cancer was lost to
follow-up five months after diagnosis. Four patients were
diagnosed three months before data collection, and are still
under follow-up without recurrence or death. Additional
follow-up is required to determine whether this difference
(wild-type in tissue and mEGFR in blood) is associated
with prognosis of lung cancer.
This analysis also reported that 22 patients showed
EGFR-mutation in tissue but not in the paired plasma sam-
ple. Of the false-negative cases, three received EGFR-TKIs
and had median PFS of 19 months. There was a longer
duration of disease control by EGFR-TKIs in the false-
negative group than the overall EGFR-TKI treated group
(19.0 vs. 13.0 months). This is probably due to the low
mutation burden, which is likely to result in a low concen-
tration of ctDNA released into the plasma and not detected
in it. To determine whether these discordant results
between tissue and blood sample affect the prognosis of
NSCLC, additional data and analysis are required.
Recent reports suggested that presence of mEGFR
ctDNA is associated with longer PFS and OS in advanced
NSCLC patients treated with EGFR-TKIs.23,24 In this study,
poor PFS and a trend toward shorter OS times were
observed in lung adenocarcinoma patients with plasma
mEGFR ctDNAs. In addition, this analysis also showed
that EGFR mutations in ctDNA were associated with
shorter duration of disease control in advanced lung ade-
nocarcinoma patients treated with EGFR-TKIs. Similar to
our results, Mok et al. and Lee et al. found that EGFR
mutations in ctDNA were correlated with poor PFS and
OS in NSCLC patients treated with EGFR-TKIs, suggesting
that presence of plasma mEGFR ctDNA predicts a poor
clinical outcome.14,25
In conclusion, plasma-based EGFR mutation analysis
using ddPCR is a highly sensitive and specific test, espe-
cially in patients with advanced NSCLC. In addition, the
detection of ctDNA with mutant EGFR is a biomarker for
predicting distant metastasis and poor response to
EGFR-TKIs.
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